1Mueller JJ,Zhou QC,Iasonos A,et al.Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center[J].Gynecol Oncol,2016,140(3):436-442.
2Griffiths CT,Fuller AF.Intensive surgical and chemotherapeutic management of advanced ovarian cancer[J].Surg Clin North Am,1978,58(1):131-142.
3Kehoe S,Hook J,Nankivell M,et al.Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer(CHORUS):an open-label,randomised,controlled,non-inferiority trial[J].Lancet,2015,386(9990):249-257.
6Vergote I,de Wever I,Tjalma W,et al.Interval debulking surgery:an alternative for primary surgical debulking?[J].Semin Surg Oncol,2000,19(1):49-53.
7Lee SJ,Kim BG,Lee JW,et al.Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery[J].J Obstet Gynaecol Res,2006,32(1):99-106.
8Hou JY,Kelly MG,Yu H,et al.Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease[J].Gynecol Oncol,2007,105(1):211-217.
10Muggia FM,Braly PS,Brady MF,et al.PhaseⅢrandomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stageⅢorⅣovarian cancer:a gynecologic oncology group study[J].J Clin Oncol,2000,18(1):106-115.
3[2]Vergote I,DeWever I,Tjalma W,et al.Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma:a retrospective analysis of 285 patients.Gynecol Oncol,1998,71:431-436.
4[3]Eisenkop SM,Spirtos NM.What are the current surgical objectives,strategies,and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol,2001,82:489 -497.
5[4]Qayyum A,Coakley FV,Westphalen AC,et al.Role of CT and MRI imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer.Gynecol Oncol,2005,96:301-306.
6[5]Chi DS,Venkatraman ES,Masson V,et al.The ability of preoperative serum CA125 to predict optimal primary tumor cytoreduction in stage Ⅲ epithelial ovarian carcinoma.Gynecol Oncol,2000,77:227-231.
7[6]Kayikcioglu F,Kose MF,Boran N,et al.Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma.Int J Gynecol Cancer,2001,11:466-470.
8[7]Kuhn W,Rutke S,Spathe K,et al.Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in Internation Federation of Gynecology and Obstetrics stage Ⅲ c ovarian carcinoma.Cancer,2001,92:2585-2591.
9Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal eytoreductive surgery for advanced ovarian carcinoma during the platinumera: a meta-analysis [J]. J Clin Oncol, 2002, 20 (5) : 1248-1259.
10Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer [ J ]. N Engl J Med, 2010, 363(10) :943-953.
